Matrifen (Fentanyl)

Matrifen (fentanyl) is used in the management of severe pain conditions that require continuous opioid delivery.

• Severe chronic non‑cancer pain: provides long‑acting analgesia to improve daily functioning.
• Cancer‑related pain: offers sustained relief for patients with advanced malignancies.
• Pain requiring continuous opioid therapy: maintains steady plasma levels to avoid breakthrough pain.

• Fentanyl binds as a high‑affinity agonist to μ‑opioid receptors in the central nervous system, inhibiting nociceptive neurotransmission and altering pain perception. Activation of these receptors reduces neuronal excitability, leading to analgesia and sedation while also modulating the release of neurotransmitters involved in pain pathways.

Fentanyl transdermal therapy can be associated with a range of adverse reactions.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Constipation: reduced bowel motility.
• Sedation: drowsiness or reduced alertness.
• Dizziness: light‑headed sensation.
• Itching at the patch site: localized skin irritation.
• Dry mouth: reduced salivation.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing.
• Severe hypotension: marked drop in blood pressure.
• Adrenal insufficiency: impaired cortisol response.
• Life‑threatening skin reactions: severe rash or necrosis.
• Overdose: potentially fatal opioid toxicity.
• QT interval prolongation: cardiac rhythm disturbance.

When prescribing Matrifen, clinicians should consider several safety measures.

• Assess pain severity: confirm that continuous opioid therapy is appropriate.
• Evaluate respiratory function: avoid in patients with compromised breathing.
• Review opioid tolerance: ensure patient is opioid‑experienced.
• Monitor for dependence: watch for signs of misuse or addiction.
• Avoid use in severe respiratory depression: contraindicated in patients with acute respiratory failure.
• Store at room temperature: keep in original pouch, protect from moisture and heat.

Fentanyl may interact with other medications, altering its safety profile.

Major Interactions (Avoid)

• Central nervous system depressants (e.g., benzodiazepines, alcohol): risk of profound sedation and respiratory depression.
• MAO inhibitors: can precipitate severe hypotension or serotonin syndrome.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase fentanyl plasma levels.
• Other opioids: additive respiratory depression.
• Respiratory depressants (e.g., barbiturates): heightened risk of respiratory failure.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.

• Diuretics: can enhance hypotensive effects.
• Antihistamines: may increase sedation.
• Certain antidepressants (e.g., SSRIs): monitor for serotonin syndrome.
• Anticholinergics: may worsen constipation.